WuXi Biologics (Cayman) Inc. is a global open-access biologics technology platform providing end-to-end solutions for the discovery, development, and manufacturing of biologics. The company offers integrated services spanning mammalian cell culture and microbial fermentation, covering product types such as monoclonal antibodies, bispecific and multispecific antibodies, Fc-fusion proteins, antibody fragments, recombinant proteins, enzymes, cytokines, antibody drug conjugates, and virus-like particles. Its business segments include research, development, and cGMP manufacturing, with capabilities in cell line development, process development, analytical testing, and drug product formulation. The group serves customers in the biologics industry across multiple regions, operating cGMP facilities in four countries. Key subsidiaries include WuXi Vaccines and WuXi XDC, the latter of which acquired a controlling stake in BioDlink International Company Limited in 2026. The company was founded in 2014.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage wuxibiologics.com
Sector Healthcare IR page wuxibiologics.com/investor-events
Tags
biologics manufacturing, contract development and manufacturing, antibody discovery, mammalian cell culture, microbial fermentation, antibody drug conjugates, vaccine development, cell line development, process development, analytical testing, WuXi Vaccines, WuXi XDC, BioDlink International Company Limited, WuXi Biologics Germany GmbH
Press page wuxibiologics.com/press-release

Metrics

Valuation  
Market cap HK$ 180.49B
Market cap (USD) $ 23.002B
P/E 31.95
PEG 8.99
P/BV 2.81
P/S 6.49
P/OCF 17.39
P/FCF —
Dividend yield —
Turnover / mcap 0.68%
Returns  
ROE 10.0%
ROI 9.1%
ROIC 9.1%
Profit margin 22.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 3.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity 0.41%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 54
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 21.79B 18.675B 17.034B 15.269B 10.29B 5.612B 3.984B 2.534B 1.619B 989.029M
Net profit 4.908B 3.356B 3.4B 4.42B 3.388B 1.689B 1.014B 630.592M 252.628M 141.096M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 34.61 10.63 28.06 51.91 67.71 86.61 86.06 42.13 45.36 —
Price performance 12m 2.33 -0.62 -0.49 -0.27 -0.16 0.01 0.98 -0.09 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Awards

October 21, 2026

Share

linkedin sharing button

wechat sharing button

WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

  • Also Named Best in Transition (Hong Kong)
  • Recognized for ESG Leadership and Green and Digital Transformation

SHANGHAI, China, October 21, 2026 – WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it received the top-honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026, as well as the Best in Transition (Hong Kong) award. WuXi Biologics is the only pharmaceutical company among this year’s Jade Award recipients.

The Jade Award — the program’s highest distinction — is conferred on organizations that integrate sustainability into strategy and operations, and demonstrate outstanding leadership in governance, resilience, innovation, transformation and long-term value creation. For WuXi Biologics, the award reflects recognition from investors and the industry of the company’s continued enhancement of ESG governance, commitment to transparent and responsible global operations, and use of sustainability to strengthen long-term competitiveness.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are honored to receive this recognition from The Asset. Sustainability is integral to our mission of enabling our clients and benefiting patients. WuXi Biologics will continue to strengthen ESG governance and advance its Green CRDMO solutions. Through innovation and responsible operations, we aim to support the pharmaceutical industry’s green transition while working with global partners to create long-term value.”

WuXi Biologics has established a four-tier governance structure led by its ESG Committee. This integrated management framework spans strategy formulation, resource allocation, professional implementation and business execution, embedding sustainability into strategic decision-making and day-to-day operations. The Company’s advanced ESG governance and sustainability performance have earned global recognition, including an MSCI AAA rating, an EcoVadis Platinum Medal, and Morningstar Sustainalytics’ highest “Negligible Risk” rating and recognition as an Industry and Regional ESG Leader, as well as inclusion in the Dow Jones Best-in-Class World Index and Emerging Markets Index.

The Asset Corporate Sustainability Leadership Awards’ Best in Transition award further recognizes WuXi Biologics’ progress in green and digital transformation. Through its end-to-end Green CRDMO solutions, the Company embeds green principles throughout the biologics research, development and manufacturing lifecycle. It continuously enhances resource efficiency and environmental performance through Green technology innovation, energy efficiency, renewable energy adoption and value-chain collaboration. WuXi Biologics also integrates digitalization with sustainability through a digital Smart ESG management platform, which strengthens data integration, dynamic monitoring and analysis, improving ESG information management efficiency and decision quality to support long-term sustainable development.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

About Us

Company

Services & Capabilities

  • Production Systems
  • Capabilities
  • Quality
  • Featured Platforms

Production Systems

  • Mammalian

    $Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.

  • Microbial

    $Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.

Mammalian$Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.

Mammalian-Derived Product Services$A true single-source provider from concept to commercialization for biologics produced from mammalian cell culture.

Mammalian-Derived Product Services

A true single-source provider from concept to commercialization for biologics produced from mammalian cell culture.

Learn more

Monoclonal Antibodies$Discover information about the various drug development services we provide for this product type

Monoclonal Antibodies

Discover information about the various drug development services we provide for this product type

Learn more

Bispecific & Multispecific Antibodies$Discover information about the various drug development services we provide for this product type

Bispecific & Multispecific Antibodies

Discover information about the various drug development services we provide for this product type

Learn more

Fc-Fusion Proteins$Discover information about the various drug development services we provide for this product type

Fc-Fusion Proteins

Discover information about the various drug development services we provide for this product type

Learn more

Antibody Fragments$Discover information about the various drug development services we provide for this product type

Antibody Fragments

Discover information about the various drug development services we provide for this product type

Learn more

Recombinant Proteins / Enzymes / Cytokines$Discover information about the various drug development services we provide for this product type

Recombinant Proteins / Enzymes / Cytokines

Discover information about the various drug development services we provide for this product type

Learn more

Antibody Drug Conjugates (ADCs)$Discover information about the various drug development services we provide for this product type

Antibody Drug Conjugates (ADCs)

Discover information about the various drug development services we provide for this product type

Learn more

Virus-Like Particles (VLPs)$Discover information about the various drug development services we provide for this product type

Virus-Like Particles (VLPs)

Discover information about the various drug development services we provide for this product type

Learn more

Microbial$Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.

Microbial Product Class$High quality, expert services for biologics produced from microbial fermentation.

Microbial Product Class

High quality, expert services for biologics produced from microbial fermentation.

Learn more

Antibody Fragments$Discover information about the various drug development services we provide for this product type

Antibody Fragments

Discover information about the various drug development services we provide for this product type

Learn more

Enzymes$Discover information about the various drug development services we provide for this product type

Enzymes

Discover information about the various drug development services we provide for this product type

Learn more

Cytokines$Discover information about the various drug development services we provide for this product type

Cytokines

Discover information about the various drug development services we provide for this product type

Learn more

Virus-Like Particles (VLPs)$Discover information about the various drug development services we provide for this product type

Virus-Like Particles (VLPs)

Discover information about the various drug development services we provide for this product type

Learn more

Capabilities

  • Research

    $Integrated Discovery Platform From Concept to IND

  • Development

    $Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.

  • Manufacturing

    $Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.

  • Testing

    $We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.

Research$Integrated Discovery Platform From Concept to IND

Antibody Discovery Services$We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.

Antibody Discovery Services

We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.

Learn more

Protein Production & Engineering Services$At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.

Protein Production & Engineering Services

At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.

Learn more

Protein Characterization Services$At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).

Protein Characterization Services

At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).

Learn more

In Vitro Assays Services$Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.

In Vitro Assays Services

Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.

Learn more

In Vivo Pharmacology Services$Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.

In Vivo Pharmacology Services

Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.

Learn more

Development$Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.

Mammalian Cell Line Development$Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.

Mammalian Cell Line Development

Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.

Learn more

Microbial Strain Development$Generate microbial strains and viral production systems from a variety of modalities.

Microbial Strain Development

Generate microbial strains and viral production systems from a variety of modalities.

Learn more

Analytical Sciences$Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.

Analytical Sciences

Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.

Learn more

Process Development & Scale Up$Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.

Process Development & Scale Up

Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.

Learn more

Late-Stage Development$Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.

Late-Stage Development

Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.

Learn more

Process Characterization$Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.

Process Characterization

Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.

Learn more

Formulation & Drug Product Development$We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.

Formulation & Drug Product Development

We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.

Learn more

Cell Banking & Characterization$Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.

Cell Banking & Characterization

Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.

Learn more

Viral Clearance$Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.

Viral Clearance

Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.

Learn more

Regulatory Support$Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.

Regulatory Support

Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.

Learn more

Manufacturing$Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.

Clinical DS GMP Manufacturing$Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.

Clinical DS GMP Manufacturing

Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.

Learn more

Clinical DP GMP Manufacturing$Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.

Clinical DP GMP Manufacturing

Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.

Learn more

Commercial DS GMP Manufacturing$We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.

Commercial DS GMP Manufacturing

We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.

Learn more

Commercial DP GMP Manufacturing$Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.

Commercial DP GMP Manufacturing

Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.

Learn more

Testing$We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.

Biosafety Testing$High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.

Biosafety Testing

High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.

Learn more

Analytical Testing$We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.

Analytical Testing

We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.

Learn more

Centers of Excellence (CoE)$Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.

Centers of Excellence (CoE)

Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.

Learn more

Global Quality Control (QC)$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).

Global Quality Control (QC)

Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).

Learn more

Quality

  • Quality & Regulatory

    $We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.

Quality & Regulatory$We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.

Global Compliance$Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.

Global Compliance

Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.

Learn more

Quality Assurance$Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.

Quality Assurance

Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.

Learn more

Quality Control$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).

Quality Control

Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).

Learn more

Regulatory Affairs$Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.

Regulatory Affairs

Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.

Learn more

Featured Platforms

Integrated Platforms$Comprehensive, high-quality, end-to-end solutions driving efficiency, decreasing time to clinic and reducing project risks from concept to commercialization.

Target to Lead$Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.

Target to Lead

Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.

Learn more

DNA to IND$Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.

DNA to IND

Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.

Learn more

IND to BLA$Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.

IND to BLA

Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.

Learn more

Discovery Technologies$A full spectrum of discovery services and technologies for the engineering, generation, characterization, optimization and selection of high-potency novel antibody therapeutics.

Bispecific and Multispecific Antibodies – WuXiBody™$The WuXiBody platform for the generation of bispecific and multispecific antibodies speeds up drug development by 6‒18 months and cuts production costs. Assembly of mAb sequence pairs into various formats with different valency optimizes flexibility.

Bispecific and Multispecific Antibodies - WuXiBody™

The WuXiBody platform for the generation of bispecific and multispecific antibodies speeds up drug development by 6‒18 months and cuts production costs. Assembly of mAb sequence pairs into various formats with different valency optimizes flexibility.

Learn more

Rapid Research Material Generation – WuXian™$Custom protein generation services, producing high-quality, research-grade proteins/antibodies by using our industry-leading team of cell culture, purification and analytical experts and high-throughput, cost-effective production technologies.

Rapid Research Material Generation - WuXian™

Custom protein generation services, producing high-quality, research-grade proteins/antibodies by using our industry-leading team of cell culture, purification and analytical experts and high-throughput, cost-effective production technologies.

Learn more

Development Technologies$Cutting-edge bioprocessing platforms and technologies designed to enable high-quality biologics to enter clinical trials faster, more efficiently and more cost-effectively.

Ultra-Intensified Fed-batch platform – WuXiUI™$Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.

Ultra-Intensified Fed-batch platform - WuXiUI™

Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.

Learn more

Cell Line Development – WuXia™$Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.

Cell Line Development - WuXia™

Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.

Learn more

Continuous Bioprocessing – WuXiUP™$This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.

Continuous Bioprocessing - WuXiUP™

This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.

Learn more

ADC Development Platform – WuXiDAR4™$Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.

ADC Development Platform - WuXiDAR4™

Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.

Learn more

High Concentration & HTP DP Platform – WuXiHigh™$Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.

High Concentration & HTP DP Platform - WuXiHigh™

Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.

Learn more

Monitoring and Predictive Control – PatroLab$Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.

Monitoring and Predictive Control - PatroLab

Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.

Learn more

Manufacturing Technologies$Advanced biomanufacturing platforms empower our global healthcare partners to deliver biologics to the clinic and on to the market for the benefit of patients worldwide.

Single-Use Bioreactors$We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.

Single-Use Bioreactors

We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.

Learn more

Scale-Out Biomanufacturing$Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.

Scale-Out Biomanufacturing

Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.

Learn more

Robotic Aseptic Filling$Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.

Robotic Aseptic Filling

Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.

Learn more

Continuous Manufacturing Process$Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.

Continuous Manufacturing Process

Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.

Learn more

Animal Health Technologies$One-stop solution for superior animal health outcomes.

Animal Health Technologies$We offer CMC-compliant, one-stop solution for animal health, to support taking drug substance and drug product from research to manufacturing.

Animal Health Technologies

We offer CMC-compliant, one-stop solution for animal health, to support taking drug substance and drug product from research to manufacturing.

Learn more

Sustainability

Sustainability

Careers

What We Value

Meet our people

Join us

Investors

Investor Events

News & Resources

WuXi Biologics

Offering End-to-End Solutions

中文 / CN

Deutsch / DE

日本語 / JP

한글 / KR

Contact Us

菜单

Press Releases

Press Releases

2026

WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity into Commercial Certainty

News

October 19, 2026

Share

linkedin sharing button

wechat sharing button

WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity into Commercial Certainty

More than 3,000 industry professionals gathered at Festival of Biologics Basel 2026 to exchange insights on the future of biologics. Extending this industry conversation, WuXi Biologics hosted its 3rd annual Basel CRDMO+ Day, convening more than 100 biotechnology and pharmaceutical leaders and experts to discuss a common challenge: how to develop, manufacture and deliver increasingly complex biologics faster, more reliably and with greater certainty.

As biologics pipelines expand beyond conventional monoclonal antibodies into bispecific antibodies, ADCs and other advanced modalities, innovators face a broader set of interconnected decisions across molecule design, manufacturability, scale-up and commercialization. Addressing these decisions early can help shorten timelines, reduce risk, and improve execution across the product lifecycle.

Scaling Complex Biologics with Greater Speed and Predictability

The biologics industry is entering a new phase of complexity. Bispecific antibodies, ADCs, and other advanced modalities now represent a growing share of innovation pipelines.

Supporting innovation at scale requires both capacity and execution. WuXi Biologics will expand annual capacity for approximately 300 IND programs and 20 BLA programs by 2027, supported by a portfolio of 1,064 integrated projects, including 399 first-in-class programs, 732 global IND clearances, and more than 90 market authorizations.

The shift toward complex molecules is already visible within this portfolio. Of the 169 projects added during the first half of 2026, 71% were bispecific antibodies or ADCs. More than two-thirds of these new programs originated from the United States and Europe, underscoring growing demand for increasingly sophisticated biologics.

Video Player

https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260902090240378.mp4

00:00

00:00

03:43

For innovators, the value of platform innovation lies in making early development faster and more predictable. The WuXia™ TrueSite Targeted Integration platform, has been adopted in 70+ projects, delivers average clone titers of 8 g/L, near-100% clone stability and significantly improved pool-to-clone consistency. These improvements can substantially reduce downstream development risk while accelerating progression toward IND.

Speed has emerged as a critical strategic lever in biologics development. WuXi Biologics introduced its clone-derived six-month DNA-to-IND solution six years ago.  Using final production clones rather than pool-derived materials, reducing future comparability risks while significantly shortening development timelines. Since its launch, the platform has been applied across 66 accelerated programs, with 6 assets advancing into late-stage and commercial manufacturing.

Identifying the Right Platform for the Right Molecule

As molecule diversity increases, selecting the right pathway and manufacturing platform has become a strategic advantage.

Rather than applying a single development model across all molecules, developers increasingly require fit-for-purpose platforms that address specific biological, manufacturability, and scale-up challenges.

To support this evolution, WuXi Biologics has expanded beyond traditional mammalian expression systems into microbial and HEK293 development platforms supporting enzymes, cytokines, antibody fragments, nanobodies, recombinant proteins, and other emerging modalities.

The microbial platform provides a strong example of this expansion. Microbial-derived biologics now represent a significant and growing portion of the biologics landscape. WuXi Biologics has accumulated experience from more than 3,000 fermentation runs across more than 140 molecules, with commercial scale-up experience reaching 15,000 liters.

Its knowledge-driven development approach has enabled:

  • 30%-50% faster development timelines
  • More than 95% first-time scale-up success rates
  • Sequence-to-GMP drug substance release in approximately 9.5 months
  • Technology transfer to BLA timelines reduced from approximately 30 months to as little as 18 months

The platform also demonstrates how process innovation drives stronger commercial economics. Across multiple programs, process optimization, scale-up strategies and raw-material improvements have generated total cost reductions of approximately 40%-50%. For developers preparing to scale, these improvements can strengthen cost competitiveness while reducing the operational burden of commercial manufacturing.

Designing for Treatment Convenience and Efficiency

For many biologics, competitive advantage is increasingly determined not only by molecular performance, but also by how therapies are designed and delivered to better meet patient needs and improve treatment convenience.

As healthcare systems push toward greater convenience and efficiency, high-concentration formulations, subcutaneous delivery and drug-device combination products are becoming critical strategic considerations much earlier in development.

WuXi Biologics has now supported:

  • More than 500 formulation and drug product processes
  • More than 180 high-concentration biologics programs
  • More than 130 programs reaching concentrations up to 240 mg/mL
  • More than 30 syringe and combination-device programs

The company’s WuXiHigh™ 2.0 platform has expanded formulation screening from 8 to 24 formulations in parallel while delivering viscosity reductions of up to 90%. These capabilities support concentration that would previously have been considered impractical for routine development and manufacturing.

Innovation continues beyond conventional high-concentration formulations. New ultra-high-concentration approaches are targeting protein concentrations up to 500 mg/mL, opening opportunities for next-generation subcutaneous and intramuscular delivery.

Hyaluronidase-enabled co-formulation has emerged as another rapidly growing area, supported by more than 30 projects. These approaches can significantly reduce administration time while improving patient convenience and product competitiveness.

As biologics grow more complex and patient needs increasingly shape product design, drug product development is becoming a strategic differentiator rather than a downstream activity.

Turning Development Know-How into Commercial Success

Scientific innovation creates value only when it can be translated into consistent commercial supply.

To help clients plan for regional supply and future demand, WuXi Biologics operates a global manufacturing network exceeding 600,000 liters of planned bioreactor capacity across Ireland, Germany, Singapore, the United States, and China. Approximately half of this capacity is located outside China, supporting a resilient global supply strategy.

The company’s commercial track record includes:

  • A 100% PPQ campaign success rate
  • More than 2,600 drug substance batches delivered with a 98.7% success rate
  • More than 2,670 drug product batches delivered with a 99.6% success rate

As biologics programs advance toward commercialization, technology transfer is becoming a critical bridge between development speed and manufacturing readiness. WuXi Biologics has completed more than 220 transfer-in projects involving more than 10 host cell lines and multiple molecule classes. Accelerated programs have achieved GMP drug substance vial thaw in less than three months, with more than 10 programs completed in under two months.

WuXi Biologics’ dual-sourcing strategy gives clients greater agility and resilience in global supply, providing a proven pathway to expand commercial production across sites with greater confidence. Several commercial products have successfully launched first in China and subsequently in Ireland, with PPQ completion at the second site occurring as little as one year while maintaining comparability and, in some cases, upgrading process performance and reducing cost.

Commercial process optimization remains a significant value driver. Through multiple commercial programs, manufacturing innovations have delivered:

  • Up to 450% titer increases
  • Up to 80% cost-of-goods reductions
  • Up to 200% productivity increases through media and process improvements

The impact extends beyond manufacturing. Programs supported by WuXi Biologics have been associated with 140 acquisitions and 42 client IPOs, demonstrating how reliable execution can help clients advance critical assets and create value at pivotal stages of company growth.

Building Predictability Through Digitalization

As biologics become more complex, the ability to translate data into actionable insights is becoming critical to reducing uncertainty and improving predictability.

WuXi Biologics is integrating digital capabilities across development, manufacturing, quality and customer collaboration to improve visibility, accelerate decision-making and strengthen execution.

Digital platforms support technology transfer, manufacturing planning, deviation investigation, process monitoring and customer engagement through a connected data environment. This includes PatroLab™, a digital manufacturing platform designed to increase process visibility, reduce risk, improve scale-up consistency and strengthen commercial robustness. Rather than reacting to variability after it occurs, the platform helps teams identify process drift earlier and convert manufacturing variability into more predictable commercial performance.

This transition toward a digital-native CRDMO aims to improve execution by combining scientific expertise, manufacturing knowledge and connected data to drive more predictable and efficient execution. Ultimately, the goal is greater visibility, earlier risk identification and increased certainty across the product lifecycle.

An Integrated Model for Biologics Success

The message from WuXi Biologics CRDMO+ Day Basel 2026 was clear.

As biologics become more complex, companies need more than access to individual technologies, manufacturing facilities or isolated service providers. They need an integrated CRDMO model that connects discovery, CMC, manufacturing, drug product development, digitalization and commercial supply within a single framework, reducing handoffs and enabling faster, better-informed decisions across the product lifecycle.

The next frontier of biologics innovation is not only about discovering more advanced molecules, but about bringing them to patients with greater speed, resilience and certainty. For innovators, an integrated partner can bridge the gap between scientific complexity and commercial success, turning complexity into a more predictable path from molecules to market.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

News

October 14, 2026

Share

linkedin sharing button

wechat sharing button

WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

  • Inclusion in the Hang Seng ESG 50 Index, signifying continued capital-market recognition of the Company’s ESG performance
  • Inclusion in the Hang Seng Corporate Sustainability Benchmark Index, reflecting the Company’s robust sustainability commitment

SHANGHAI, China, October 14, 2026 – WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that the Company has continued to be included in multiple Hang Seng sustainability indexes — notably the Hang Seng ESG 50 Index and the Hang Seng Corporate Sustainability Benchmark Index —once again demonstrating its excellence in environmental, social and governance (ESG) performance.

Since 2014, the Hang Seng Indexes Company has appointed the Hong Kong Quality Assurance Agency (HKQAA), an independent and professional assessment body, to conduct annual evaluations of listed companies’ sustainability performance. The assessment framework covers three core aspects – Environmental, Social, and Governance – and incorporates materiality factors specific to different industries. The ratings serve as a benchmark for evaluating corporate ESG performance and are used in the selection of constituents for the Hang Seng Company’s Sustainability Indexes.

In 2026, the HKQAA sustainability assessment covered approximately 600 Hong Kong-listed constituents of the Hang Seng Composite Index and over 1,300 A-share constituents of the Hang Seng China A (Investable) Index. WuXi Biologics received an A+ rating in this year’s HKQAA assessment. As a leading global biologics CRDMO, WuXi Biologics regards sustainability as a cornerstone of long-term business growth and integrates it into corporate strategy and operations. Driven by its commitment to Green CRDMO, the Company resolutely advances green biologics research, development, manufacturing and operations. Through innovative technologies, lean management and digital capabilities, it continuously enhances resource efficiency and operational resilience while driving higher quality and more efficient green operations.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, commented:

“Our continued inclusion in multiple Hang Seng sustainability indexes underscores strong recognition of WuXi Biologics’ long-standing commitment to sustainability and its Green CRDMO solutions. We firmly believe that sustainability is not only an important foundation for long-term business growth, but also a key driver of industry innovation and shared value creation. Looking ahead, WuXi Biologics will remain dedicated to lasting value for clients, patients, society, and the planet through innovative technologies and responsible operations, while contributing to the advancement of sustainable development within the global biopharmaceutical industry.”

In recent years, WuXi Biologics has continually received international recognition for its sustainability performance, including the highest MSCI ESG Rating of AAA; the EcoVadis Platinum Medal, placing the Company among the top 1% globally; inclusion in the Dow Jones Best-in-Class World Index and Dow Jones Best-in-Class Emerging Markets Index; inclusion on CDP’s A Lists for Climate Change, Water Security and Supplier Engagement Assessment; Morningstar Sustainalytics’ highest “Negligible Risk” rating and recognition as an Industry and Regional ESG leader; and inclusion in the FTSE4Good Index Series. These recognitions reflect not only the Company’s ongoing progress across environmental, social and governance areas, but also stakeholder recognition of its sustainability strategy, governance capabilities and performance.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

Prompts

Wuxi Biologics (Cayman) Inc. (ticker 2269), listed in Hong Kong.

ETFs Holding Wuxi Biologics (Cayman) Inc.

ETF Weight in ETF Shares Market value As of
MEMA 1.17% 23,500 $ 146.408K Aug 31, 2026
EMSF 0.87% 94,500 $ 416.945K Jun 30, 2026
NBCE 0.52% 15,200 $ 94.709K Aug 31, 2026
EMMF 0.40% 163,000 $ 719.174K Jun 30, 2026
AVSE 0.38% 137,500 $ 810.856K Nov 16, 2026
DFSE 0.32% 295,500 $ 1.841M Nov 12, 2026
AVEM 0.26% 11,684,500 $ 68.905M Nov 16, 2026
DFEM 0.20% 2,815,000 $ 17.54M Nov 12, 2026
DFAE 0.17% 2,525,000 $ 15.733M Nov 12, 2026
REMG 0.16% 39,000 $ 172.055K Jun 30, 2026
NTSE 0.14% 18,000 $ 79.418K Jun 30, 2026
DFAX 0.09% 1,791,000 $ 11.16M Nov 12, 2026
DFEV 0.00% 1,000 $ 6,231.00 Nov 12, 2026